Related Experiment Videos
[Chromosome 22q11 and schizophrenia]
1Laboratory of Molecular Psychobiology, Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA.
Summary
Chromosome 22q11 deletion, linked to velo-cardio-facial syndrome/DiGeorge syndrome, is associated with schizophrenia. Mouse studies identify Tbx1, Prodh, and Comt genes on chromosome 16 as key contributors, aiding understanding of this neuropsychiatric disorder.
Area of Science:
- Genetics
- Neuropsychiatry
- Developmental Biology
Context:
- Schizophrenia is a complex neuropsychiatric disorder with suspected genetic underpinnings.
- Chromosome 22q11 deletion syndrome (22q11DS) presents with physical anomalies and elevated schizophrenia risk.
- Mouse models are crucial for dissecting the genetic architecture of complex human disorders.
Purpose:
- To investigate the genetic basis of schizophrenia within the context of 22q11DS.
- To identify candidate genes on mouse chromosome 16 homologous to human 22q11 that contribute to VCFS/DGS phenotypes.
- To elucidate the role of specific genes (Tbx1, Prodh, Comt) in the pathogenesis of VCFS/DGS and its link to schizophrenia.
Summary:
- Human chromosome 22q11 deletions are implicated in velo-cardio-facial syndrome/DiGeorge syndrome (VCFS/DGS) and increased schizophrenia susceptibility.
- Mouse chromosome 16 harbors homologs of VCFS/DGS candidate genes, including Tbx1, Prodh, and Comt.
- Deletion of these mouse genes results in phenotypes mirroring VCFS/DGS, suggesting a conserved genetic role.
Impact:
- Identifying the genetic factors contributing to VCFS/DGS can illuminate specific subtypes of schizophrenia.
- This research advances the understanding of the genetic etiology of schizophrenia and related neuropsychiatric conditions.
- Pinpointing genetic contributions to VCFS/DGS may lead to targeted therapeutic strategies for schizophrenia.